NSEAnalysts/Institutional Investor Meet/Con. Call Updates1d ago · 21 Sept 2026, 02:52 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Glenmark Pharmaceuticals Limited · GLENMARK
✦ AI Summary
Glenmark Pharmaceuticals has informed the Exchange about the schedule of an Analyst/ Institutional Investor meeting to be conducted on 29-09-2026 at PL Capital - Emerging Titans Mumbai Physical Both 2026 Conference.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Glenmark Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
GLENMARK_21092026145007_SE_Investor_Meet.pdf
View document text
September 21, 2026
To, To,
National Stock Exchange of India Limited, BSE Limited,
“Exchange Plaza”, Corporate Relationship Department,
5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring,
Bandra- Kurla Complex, Bandra (East), P.J. Towers, Dalal Street,
Mumbai – 400 051 Mumbai – 400 001
Scrip Name: GLENMARK Scrip Code: 532296
ISIN: INE935A01035 ISIN: INE935A01035
Our Reference No. 56/26-27 Our Reference No. 56/26-27
Dear Sir/ Madam,
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (“SEBI LODR”) - Schedule of Analyst/ Institutional Investor Meetings
With reference to the captioned subject and pursuant to the Regulation 30 and Para A of Part A of
Schedule III of the SEBI LODR, we would like to inform details of the Analyst/ Institutional Investor meeting
to be conducted as follows:
Analyst/Institutional Type of Group /
Date Venue
Investors/Event Meeting One-on-one
29-09-2026 PL Capital - Emerging Titans Mumbai Physical Both
2026 Conference
The schedule of the above-mentioned meeting may undergo changes due to exigencies on the part of
Investor/ Company.
Kindly note that no unpublished price sensitive information is proposed to be shared during the meeting.
We request you to take this intimation on record.
Thanking you.
Yours faithfully,
For Glenmark Pharmaceuticals Limited
Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839
Glenmark Pharmaceuticals Limited
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com